title: [Dynamics of primary hemostasis activity in patients with arterial hypertension and metabolic syndrome treated with candesartan].
abstract: The aim of the study was to elucidate normalizing effect of candesartan on disturbed thrombocytic hemostasis in patients with arterial hypertension and metabolic syndrome. The drug was given for 16 weeks to 31 patients in whom dynamics of lipid peroxidation in plasma and platelets, the antioxidative potential of candesartan, and parameters of thrombocytic hemostasis were assessed. Treatment with candesartan improved lipid peroxidation and primary hemostasis. It is expected that continuation of therapy following this scheme can stabilize the obtained effect.
authors.forename: V B
authors.initials: VB
authors.lastname: Simonenko
authors.forename: I N
authors.initials: IN
authors.lastname: Medvedev
authors.forename: V V
authors.initials: VV
authors.lastname: Tolmachev
mesh_terms: D047228:Angiotensin II Type 1 Receptor Blockers / Q000627:therapeutic use*; D001562:Benzimidazoles / Q000627:therapeutic use*; D001713:Biphenyl Compounds; D001794:Blood Pressure / Q000187:drug effects; D005260:Female; D005500:Follow-Up Studies; D006487:Hemostasis / Q000187:drug effects / Q000502:physiology*; D006801:Humans; D006973:Hypertension / Q000097:blood* / Q000188:drug therapy / Q000503:physiopathology; D015227:Lipid Peroxidation / Q000187:drug effects / Q000502:physiology*; D008297:Male; D024821:Metabolic Syndrome / Q000097:blood* / Q000188:drug therapy / Q000503:physiopathology; D008875:Middle Aged; D013777:Tetrazoles / Q000627:therapeutic use*; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D047228:Angiotensin II Type 1 Receptor Blockers; D001562:Benzimidazoles; D001713:Biphenyl Compounds; D013777:Tetrazoles; C081643:candesartan